首页 > 市场调查报告书 > 製药

全球膀胱过动症治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

市场调查报告书

商品编码

1408982

全球膀胱过动症治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Overactive Bladder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 248 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2030 年，全球膀胱过动症治疗市场的市场规模将从 2022 年的 43.3 亿美元达到近 65.4 亿美元，2023-2030 年研究期间CAGR为 5.29%。

膀胱过动症 (OAB) 的治疗涉及多种方法来控制与这种情况相关的症状。 OAB 的特征是膀胱壁肌肉突然不自主地收缩，导致频繁、紧急的排尿需求。该治疗旨在缓解症状并改善个人的生活品质。

市场动态

膀胱过动症 (OAB) 治疗市场由几个关键因素驱动。主要原因是 OAB 盛行率不断上升，特别是在老化人口中，导致对有效治疗方案的需求不断增加。医学研究和药物创新的进步发挥着至关重要的作用，标靶药物的开发可提高疗效并减少副作用。人们越来越认识到行为疗法和生活方式改变是 OAB 的有效一线治疗方法，这进一步塑造了市场。这种向非侵入性方法的转变有助于扩大行为治疗计画和相关干预措施的市场。在设备和手术技术进步的推动下，对其他治疗方法抗药性的 OAB 病例的神经调节疗法和手术干预也影响着市场。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球膀胱过动症治疗市场的每个细分市场进行了包容性评估。膀胱过动症治疗产业的成长和趋势为本研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲膀胱过动症治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。膀胱过动症治疗市场的主要参与者包括辉瑞公司、艾伯维公司、安斯泰来製药公司、美敦力公司、住友製药美国公司（Urovant Sciences.）、Viatris Inc.、梯瓦製药工业有限公司、久光製药Co., Inc.、Macleods Pharmaceuticals Ltd.、Endo International plc。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：膀胱过动症治疗公司的竞争格局

膀胱过动症治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

公司股份分析
市场集中度
Pfizer Inc.

公司简介
公司收入
产品
最近的发展

AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Astellas Pharma Inc.

公司简介
公司收入
产品
最近的发展

Medtronic

公司简介
公司收入
产品
最近的发展

Sumitomo Pharma America Inc.( Urovant Sciences.)

公司简介
公司收入
产品
最近的发展

Viatris Inc.

公司简介
公司收入
产品
最近的发展

Teva Pharmaceutical Industries Ltd.

公司简介
公司收入
产品
最近的发展

Hisamitsu Pharmaceutical Co. Inc

公司简介
公司收入
产品
最近的发展

Macleods Pharmaceuticals Ltd.

公司简介
公司收入
产品
最近的发展

Endo International plc

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112113273

The global demand for Overactive Bladder Treatment Market is presumed to reach the market size of nearly USD 6.54 BN by 2030 from USD 4.33 BN in 2022 with a CAGR of 5.29% under the study period 2023 - 2030.

Overactive bladder (OAB) treatment involves various approaches to managing the symptoms associated with this condition. OAB is characterized by a sudden, involuntary contraction of the muscles in the bladder wall, leading to a frequent and urgent need to urinate. The treatment aims to alleviate symptoms and improve the individual's quality of life.

MARKET DYNAMICS

The Overactive Bladder (OAB) Treatment market is driven by several key factors. A primary contributor is the increasing prevalence of OAB, particularly among the aging population, leading to a rising demand for effective treatment options. Advancements in medical research and pharmaceutical innovation play a crucial role, with the development of targeted medications offering improved efficacy and fewer side effects. The market is further shaped by the growing recognition of behavioral therapies and lifestyle modifications as effective first-line treatments for OAB. This shift towards non-invasive approaches contributes to the expansion of the market for behavioral therapy programs and related interventions. Neuromodulation therapies and surgical interventions for OAB cases resistant to other treatments also influence the market, driven by technological advancements in devices and procedures.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of overactive bladder treatment. The growth and trends of overactive bladder treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the overactive bladder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Anticholinergics
Mirabegron
Botox
Neuromodulation
Other

By Disease Type

Idiopathic Overactive Bladder
Neurogenic Overactive Bladder

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Overactive Bladder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Overactive Bladder Treatment market include Pfizer, Inc., AbbVie Inc., Astellas Pharma Inc., Medtronic, Sumitomo Pharma America, Inc.( Urovant Sciences.), Viatris Inc., Teva Pharmaceutical Industries Ltd., Hisamitsu Pharmaceutical Co., Inc, Macleods Pharmaceuticals Ltd., Endo International plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . OVERACTIVE BLADDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Disease Type
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Anticholinergics Historic and Forecast Sales by Regions
5.5 Mirabegron Historic and Forecast Sales by Regions
5.6 Botox Historic and Forecast Sales by Regions
5.7 Neuromodulation Historic and Forecast Sales by Regions
5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISEASE TYPE

6.1 Overview by Disease Type
6.2 Historical and Forecast Data
6.3 Analysis by Disease Type
6.4 Idiopathic Overactive Bladder Historic and Forecast Sales by Regions
6.5 Neurogenic Overactive Bladder Historic and Forecast Sales by Regions

7 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE OVERACTIVE BLADDER TREATMENT COMPANIES

9.1. Overactive Bladder Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF OVERACTIVE BLADDER TREATMENT INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. AbbVie Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Astellas Pharma Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Medtronic
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Sumitomo Pharma America Inc.( Urovant Sciences.)
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Viatris Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Teva Pharmaceutical Industries Ltd.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Hisamitsu Pharmaceutical Co. Inc
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Macleods Pharmaceuticals Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Endo International plc
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments